Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

DVA

DaVita Inc

May 17 • 04:00PM ET

139.82

Dollar change +3.34
Percentage change 2.45	%

Healthcare • Medical Care Facilities • USA • NYSE

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: COWZ VTI VOO VB VBR RSP IVV IWP FXH VHT

Index	S&P 500	P/E	15.88	EPS (ttm)	8.81	Insider Own	1.52%	Shs Outstand	88.82M	Perf Week	1.67%
Market Cap	12.26B	Forward P/E	13.19	EPS next Y	10.60	Insider Trans	-9.93%	Shs Float	86.37M	Perf Month	10.87%
Income	815.64M	PEG	1.23	EPS next Q	2.55	Inst Own	90.09%	Short Float	4.08%	Perf Quarter	14.40%
Sales	12.34B	P/S	0.99	EPS this Y	13.37%	Inst Trans	-2.64%	Short Ratio	4.42	Perf Half Y	48.00%
Book/sh	10.56	P/B	13.24	EPS next Y	10.37%	ROA	4.78%	Short Interest	3.52M	Perf Year	41.79%
Cash/sh	5.03	P/C	27.78	EPS next 5Y	12.90%	ROE	93.14%	52W Range	71.51 - 145.04	Perf YTD	33.47%
Dividend Est.	-	P/FCF	13.23	EPS past 5Y	51.82%	ROI	6.66%	52W High	-3.60%	Beta	0.94
Dividend TTM	-	Quick Ratio	1.37	Sales past 5Y	1.27%	Gross Margin	26.28%	52W Low	95.53%	ATR (14)	3.31
Dividend Ex-Date	-	Current Ratio	1.43	EPS Y/Y TTM	67.23%	Oper. Margin	14.09%	RSI (14)	59.07	Volatility	1.72% 2.62%
Employees	70000	Debt/Eq	12.79	Sales Y/Y TTM	5.77%	Profit Margin	6.61%	Recom	2.90	Target Price	146.07
Option/Short	Yes / Yes	LT Debt/Eq	12.22	EPS Q/Q	111.84%	Payout	0.00%	Rel Volume	0.95	Prev Close	136.48
Sales Surprise	1.41%	EPS Surprise	22.18%	Sales Q/Q	6.89%	Earnings	May 02 AMC	Avg Volume	795.82K	Price	139.82
SMA20	2.78%	SMA50	3.49%	SMA200	27.26%	Trades		Volume	758,497	Change	2.45%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-06-24	Initiated	Barclays	Equal Weight	$133
Aug-07-23	Upgrade	UBS	Neutral → Buy	$100 → $142
Nov-01-22	Downgrade	Deutsche Bank	Buy → Hold	$97 → $72
Oct-31-22	Downgrade	UBS	Buy → Neutral	$117 → $74
Aug-19-22	Resumed	UBS	Buy	$106 → $117
Jun-21-22	Reiterated	BofA Securities	Underperform	$110 → $90
Sep-10-21	Initiated	Cowen	Market Perform	$145
Aug-12-21	Downgrade	Barclays	Overweight → Equal Weight	$135 → $146
Mar-26-21	Downgrade	BofA Securities	Neutral → Underperform	$127 → $118
Jan-05-21	Downgrade	BofA Securities	Buy → Neutral	$127
Jan-24-20	Upgrade	Goldman	Neutral → Buy	$72 → $97
Nov-07-19	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-25-19	Downgrade	Wolfe Research	Outperform → Peer Perform
Sep-11-19	Downgrade	William Blair	Outperform → Mkt Perform
Jul-26-19	Downgrade	Robert W. Baird	Outperform → Neutral	$70 → $65
Jan-08-19	Upgrade	UBS	Sell → Neutral
Jan-03-19	Initiated	Deutsche Bank	Buy	$60
Dec-14-18	Initiated	Barclays	Overweight
Nov-28-18	Upgrade	Raymond James	Mkt Perform → Outperform
Nov-16-18	Initiated	UBS	Sell	$64

Show Previous Ratings

May-16-24 08:55AM	Warren Buffett's Top Favorite Stocks for 2024 (Insider Monkey)
May-15-24 06:14AM	Truist Securities Raises Price Target on DaVita to $150 From $135, Keeps Hold Rating (MT Newswires)
May-14-24 09:00AM	DaVita Celebrates Corporate Citizenship Achievements with Release of 2023 Community Care Report (PR Newswire)
May-13-24 09:00AM	DaVita Appoints New Chief Information Officer (PR Newswire)
May-12-24 09:52AM	P3 Health Partners Inc. (NASDAQ:PIII) Q1 2024 Earnings Call Transcript (Insider Monkey)
06:15PM	Loading…
May-09-24 06:15PM	DaVita Inc. to Participate in the BofA Securities 2024 Health Care Conference (PR Newswire)
12:00PM	Are You Looking for a Top Momentum Pick? Why DaVita HealthCare (DVA) is a Great Choice (Zacks)
10:00AM	DaVita Honors 54 Nephrology Nurses with DAISY Awards (PR Newswire)
May-07-24 09:40AM	Are Medical Stocks Lagging DaVita (DVA) This Year? (Zacks)
08:01AM	TD Cowen Adjusts Price Target on DaVita to $139 From $136 (MT Newswires)
May-06-24 09:40AM	Is DaVita (DVA) a Great Value Stock Right Now? (Zacks)
09:40AM	DaVita HealthCare (DVA) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
09:15AM	DaVita Inc. (DVA) Hits Fresh High: Is There Still Room to Run? (Zacks)
May-03-24 04:03PM	Tandem Diabetes Catapults Above A Profit-Taking Zone, But DaVita Flashes A Sell Signal (Investor's Business Daily) -5.48%
12:22PM	DaVita (DVA) Q1 Earnings & Revenues Top Estimates, Margins Up (Zacks)
11:17AM	Loading…
11:17AM	DaVita Inc. (NYSE:DVA) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:46AM	UBS Adjusts Price Target on DaVita to $169 From $145, Maintains Buy Rating (MT Newswires)
09:03AM	The Big Split: 3 Stock Spinoffs Are Coming. Should You Buy? (InvestorPlace)
08:55AM	Q1 2024 DaVita Inc Earnings Call (Thomson Reuters StreetEvents)
08:36AM	Deutsche Bank Adjusts Price Target on DaVita to $145 From $135 (MT Newswires)
08:21AM	Barclays Adjusts Price Target on DaVita to $150 From $133 (MT Newswires)
04:08AM	DaVita Inc (DVA) Q1 2024 Earnings Call Transcript Highlights: Key Financial Updates and ... (GuruFocus.com)
02:22AM	Analyst Report: DaVita Inc. (Morningstar Research)
01:16AM	Decoding DaVita Inc (DVA): A Strategic SWOT Insight (GuruFocus.com)
May-02-24 11:15PM	DaVita (DVA) Q1 2024 Earnings Call Transcript (Motley Fool)
08:57PM	DVA Stock Earnings: DaVita Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:44PM	DaVita Inc. (DVA) Q1 2024 Earnings: Surpasses Revenue and EPS Estimates (GuruFocus.com)
05:15PM	DaVita HealthCare (DVA) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
05:07PM	DaVita Q1 Adjusted Earnings, Revenue Rise; 2024 EPS Guidance Range Narrows; Shares Gain After Hours (MT Newswires)
04:17PM	DaVita HealthCare: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	DaVita Inc. 1st Quarter 2024 Results (PR Newswire)
May-01-24 01:04PM	Strength in Kidney Care Likely to Aid DaVita's (DVA) Q1 Earnings (Zacks)
10:47AM	3 Healthcare Stocks With the Potential to Triple Your Investment by 2026 (InvestorPlace)
Apr-27-24 06:10AM	Warren Buffett's 3 Best-Performing Stocks So Far in 2024: Are They Buys Now? (Motley Fool)
Apr-25-24 05:50PM	DaVita HealthCare (DVA) Increases Despite Market Slip: Here's What You Need to Know (Zacks)
Apr-23-24 09:00AM	Is Trending Stock DaVita Inc. (DVA) a Buy Now? (Zacks)
07:45AM	Garry Menzel joins GHO Capital as Operating Partner (GlobeNewswire)
Apr-22-24 04:22PM	Ford, Nvidia Among Top S&P 500 Stocks Monday; Tesla Extends Losses (Investor's Business Daily)
09:00AM	DaVita's Global Operations Powered by 100% Renewable Energy (PR Newswire)
Apr-19-24 05:50PM	DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors (Zacks)
Apr-18-24 06:00PM	DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
09:40AM	Here's Why DaVita HealthCare (DVA) is a Strong Value Stock (Zacks)
Apr-17-24 07:31PM	DaVita Inc. Schedules 1st Quarter 2024 Investor Conference Call (PR Newswire)
Apr-12-24 05:50PM	DaVita HealthCare (DVA) Stock Moves -0.75%: What You Should Know (Zacks)
Apr-10-24 01:35PM	Here's Why You Should Add DaVita (DVA) to Your Portfolio (Zacks)
09:40AM	Should Value Investors Buy DaVita (DVA) Stock? (Zacks)
09:00AM	Is Most-Watched Stock DaVita Inc. (DVA) Worth Betting on Now? (Zacks)
09:00AM	DaVita Announces Dennis Pullin to its Board of Directors (PR Newswire)
Apr-08-24 06:00PM	Why the Market Dipped But DaVita HealthCare (DVA) Gained Today (Zacks)
Apr-02-24 09:40AM	Here's Why DaVita HealthCare (DVA) is a Strong Value Stock (Zacks)
Mar-25-24 10:59AM	What Makes Fresenius Medical Care AG (FMS) a Potential Investment? (Insider Monkey)
10:46AM	Is this the Best Time to Add DaVita (DVA) to Your Portfolio? (Insider Monkey)
09:40AM	Are Investors Undervaluing DaVita (DVA) Right Now? (Zacks)
Mar-24-24 05:49AM	Warren Buffett's Berkshire Hathaway Owns Over 25% of These 4 Companies (Hint: Apple Isn't One of Them) (Motley Fool)
Mar-22-24 09:52AM	Rockwell Medical, Inc. (NASDAQ:RMTI) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-21-24 12:00PM	DaVita HealthCare (DVA) Is Up 1.09% in One Week: What You Should Know (Zacks)
Mar-19-24 05:10AM	3 No-Brainer Warren Buffett Stocks to Buy Right Now (Motley Fool)
Mar-15-24 09:40AM	Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term (Zacks)
Mar-14-24 11:30AM	DaVita HealthCare (DVA) Up 12% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-11-24 04:40PM	The American Diabetes Association and DaVita Strengthen Alliance to Tackle Chronic Disease Head-On (PR Newswire)
Mar-08-24 05:20PM	DaVita Inc. to Participate in the Barclays Global Healthcare Conference 2024 (PR Newswire)
09:40AM	Should Value Investors Buy DaVita (DVA) Stock? (Zacks)
05:44AM	Davita (DVA) Shares Gain This Week: Will the Rally Continue? (Zacks)
Mar-06-24 10:09AM	DaVita (DVA) Hits 52-Week High: What's Driving the Stock? (Zacks)
09:49AM	DaVita (DVA) Expands Operational Footprint Via New Agreement (Zacks)
09:15AM	DaVita Inc. (DVA) Hit a 52 Week High, Can the Run Continue? (Zacks)
Mar-05-24 04:50PM	S&P 500 Gains and Losses Today: Target Stock Jumps After Strong Holiday Quarter (Investopedia) +7.09%
04:19PM	Why Dialysis Stocks DaVita, Fresenius Soared On Novo's Ozempic News (Investor's Business Daily)
03:34PM	Why Dialysis Stocks Are up Today (The Wall Street Journal)
10:08AM	Analyst Report: DaVita Inc. (Morningstar Research)
09:00AM	DaVita enters into agreement to expand operations in Brazil and Colombia, enter Chile and Ecuador (PR Newswire)
Feb-29-24 07:19PM	DaVita Inc. to Participate in the TD Cowen's Health Care Conference 2024 (PR Newswire)
Feb-28-24 11:23PM	DaVita Inc CEO Javier Rodriguez Sells 75,000 Shares (GuruFocus.com)
Feb-27-24 07:47AM	Warren Buffett 2024 Portfolio: Top 12 Stock Picks (Insider Monkey)
Feb-23-24 12:00PM	Are You Looking for a Top Momentum Pick? Why DaVita HealthCare (DVA) is a Great Choice (Zacks)
Feb-22-24 10:31AM	3 Cheap Stocks to Buy Now for Fast Gains (InvestorPlace)
09:50AM	Here's Why DaVita HealthCare (DVA) is a Strong Momentum Stock (Zacks)
Feb-21-24 12:20PM	Earnings Estimates Moving Higher for DaVita HealthCare (DVA): Time to Buy? (Zacks)
09:40AM	Should Value Investors Buy DaVita (DVA) Stock? (Zacks)
Feb-20-24 01:53AM	UPDATE 2-FMC sees higher earnings in 2024, says few patients on GLP-1s (Reuters)
Feb-15-24 09:15AM	DaVita Inc. (DVA) Soars to 52-Week High, Time to Cash Out? (Zacks)
08:50AM	DaVita Inc. (NYSE:DVA) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:22AM	Decoding DaVita Inc (DVA): A Strategic SWOT Insight (GuruFocus.com)
Feb-14-24 07:08PM	Why DaVita Stock Popped Today (Motley Fool) +8.64%
11:44AM	DaVita Stock Is Having Its Best Day in Years. Volumes Are Improving After Covid-19. (Barrons.com)
09:10AM	DaVita (DVA) Q4 Earnings & Revenues Top Estimates, Margins Up (Zacks)
Feb-13-24 08:14PM	Analyst Report: DaVita Inc. (Morningstar Research)
08:00PM	DaVita (DVA) Q4 2023 Earnings Call Transcript (Motley Fool)
05:20PM	DaVita HealthCare (DVA) Q4 Earnings and Revenues Top Estimates (Zacks)
04:50PM	DaVita HealthCare: Q4 Earnings Snapshot (Associated Press Finance)
04:36PM	DaVita Inc (DVA) Reports Solid Financial Performance Amid Operational Challenges (GuruFocus.com)
04:08PM	DaVita Inc. 4th Quarter 2023 Results (PR Newswire)
Feb-12-24 06:02AM	Meet the Most Ridiculously Cheap Stock in Warren Buffett's Berkshire Hathaway Portfolio (Motley Fool)
Feb-09-24 10:51AM	DaVita (DVA) to Report Q4 Earnings: What's in the Offing? (Zacks)
06:15AM	2 Best Warren Buffett Stocks to Buy for the Long Haul (Motley Fool)
Feb-01-24 09:40AM	Are Investors Undervaluing DaVita (DVA) Right Now? (Zacks)
Jan-31-24 03:55PM	Earn a 5.79% Dividend Yield from DaVita Stock Using This Hack (Benzinga)
Jan-23-24 02:00PM	DaVita Inc. Schedules 4th Quarter 2023 Investor Conference Call (PR Newswire)
Jan-22-24 09:50AM	Why DaVita HealthCare (DVA) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-19-24 09:40AM	Here's Why DaVita HealthCare (DVA) is a Strong Value Stock (Zacks)

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DESOER BARBARA J	Director	May 10 '24	Sale	138.81	5,030	698,214	10,954	May 14 05:44 PM
STAFFIERI MICHAEL DAVID	Chief Operating Officer, DKC	Mar 13 '24	Option Exercise	52.41	50,000	2,620,500	102,748	Mar 15 06:13 PM
Rodriguez Javier	Chief Executive Officer	Mar 06 '24	Option Exercise	67.80	750,000	50,850,000	1,244,480	Mar 08 05:04 PM
ACKERMAN JOEL	CFO and Treasuer	Mar 06 '24	Option Exercise	52.41	55,000	2,882,550	195,360	Mar 08 05:04 PM
STAFFIERI MICHAEL DAVID	Chief Operating Officer, DKC	Mar 06 '24	Option Exercise	52.41	50,000	2,620,500	87,687	Mar 08 05:05 PM
Rodriguez Javier	Chief Executive Officer	Feb 28 '24	Option Exercise	67.80	50,000	3,390,000	531,300	Feb 28 05:51 PM
Rodriguez Javier	Chief Executive Officer	Feb 27 '24	Sale	126.87	7,397	938,467	481,300	Feb 28 05:51 PM
Rodriguez Javier	Chief Executive Officer	Feb 26 '24	Option Exercise	67.80	450,000	30,510,000	889,002	Feb 28 05:51 PM
Rodriguez Javier	Chief Executive Officer	Feb 26 '24	Sale	126.11	67,603	8,525,130	488,697	Feb 28 05:51 PM
STAFFIERI MICHAEL DAVID	Chief Operating Officer, DKC	Feb 21 '24	Option Exercise	52.41	100,000	5,241,000	137,687	Feb 23 05:44 PM
ACKERMAN JOEL	CFO and Treasuer	Feb 21 '24	Option Exercise	52.41	55,000	2,882,550	178,726	Feb 23 05:43 PM
Waters Kathleen Alyce	Chief Legal & Pub. Affairs Off	Feb 21 '24	Option Exercise	52.41	40,000	2,096,400	121,297	Feb 23 05:44 PM
STAFFIERI MICHAEL DAVID	Chief Operating Officer, DKC	Feb 21 '24	Sale	119.81	29,488	3,533,025	37,687	Feb 23 05:44 PM
Waters Kathleen Alyce	Chief Legal & Pub. Affairs Off	Feb 21 '24	Sale	120.73	11,285	1,362,438	81,297	Feb 23 05:44 PM
HEARTY JAMES O	Chief Compliance Officer	Feb 16 '24	Option Exercise	54.40	54,608	2,970,478	78,448	Feb 20 08:37 PM
HEARTY JAMES O	Chief Compliance Officer	Feb 16 '24	Sale	119.64	26,164	3,130,269	20,264	Feb 20 08:37 PM
Rodriguez Javier	Chief Executive Officer	Dec 14 '23	Option Exercise	67.80	500,000	33,900,000	833,299	Dec 18 06:44 PM
Waters Kathleen Alyce	Chief Legal & Pub. Affairs Off	Aug 22 '23	Option Exercise	52.41	40,000	2,096,400	121,297	Aug 24 06:54 PM
Waters Kathleen Alyce	Chief Legal & Pub. Affairs Off	Aug 22 '23	Sale	101.81	9,794	997,099	81,297	Aug 24 06:54 PM

Open in Screener

GILD

Gilead Sciences, Inc.

May 17 • 04:00PM ET

67.72

Dollar change -0.14
Percentage change -0.21	%

Healthcare • Drug Manufacturers - General • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO QQQ IVV VTV IBB COWZ VYM MOAT VHT

Index	NDX, S&P 500	P/E	188.79	EPS (ttm)	0.36	Insider Own	0.10%	Shs Outstand	1.25B	Perf Week	2.67%
Market Cap	84.37B	Forward P/E	9.47	EPS next Y	7.15	Insider Trans	-2.00%	Shs Float	1.24B	Perf Month	2.36%
Income	484.00M	PEG	35.06	EPS next Q	1.59	Inst Own	85.59%	Short Float	1.70%	Perf Quarter	-5.39%
Sales	27.42B	P/S	3.08	EPS this Y	-43.91%	Inst Trans	0.85%	Short Ratio	3.01	Perf Half Y	-9.75%
Book/sh	14.08	P/B	4.81	EPS next Y	89.63%	ROA	0.82%	Short Interest	21.16M	Perf Year	-14.07%
Cash/sh	4.86	P/C	13.92	EPS next 5Y	5.38%	ROE	2.51%	52W Range	64.33 - 87.86	Perf YTD	-16.41%
Dividend Est.	3.13 (4.62%)	P/FCF	10.68	EPS past 5Y	1.55%	ROI	1.24%	52W High	-22.93%	Beta	0.23
Dividend TTM	3.02 (4.46%)	Quick Ratio	0.94	Sales past 5Y	4.16%	Gross Margin	77.68%	52W Low	5.27%	ATR (14)	1.13
Dividend Ex-Date	Jun 14, 2024	Current Ratio	1.08	EPS Y/Y TTM	-91.37%	Oper. Margin	34.04%	RSI (14)	53.33	Volatility	1.66% 1.74%
Employees	18000	Debt/Eq	1.44	Sales Y/Y TTM	2.13%	Profit Margin	1.77%	Recom	2.18	Target Price	82.25
Option/Short	Yes / Yes	LT Debt/Eq	1.23	EPS Q/Q	-517.48%	Payout	66.62%	Rel Volume	0.51	Prev Close	67.86
Sales Surprise	5.17%	EPS Surprise	11.60%	Sales Q/Q	5.66%	Earnings	Apr 25 AMC	Avg Volume	7.02M	Price	67.72
SMA20	2.47%	SMA50	-2.41%	SMA200	-10.36%	Trades		Volume	3,575,952	Change	-0.21%

Date	Action	Analyst	Rating Change	Price Target Change
May-01-24	Reiterated	Maxim Group	Buy	$90 → $85
Apr-24-24	Upgrade	HSBC Securities	Reduce → Hold	$69
Feb-22-24	Downgrade	Truist	Buy → Hold	$91 → $82
Nov-09-23	Initiated	Deutsche Bank	Hold	$75
Sep-08-23	Upgrade	BofA Securities	Neutral → Buy	$88 → $95
Sep-06-23	Initiated	HSBC Securities	Reduce	$71
Jul-24-23	Reiterated	Barclays	Equal Weight	$81 → $80
May-16-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$90 → $100
Apr-28-23	Resumed	Piper Sandler	Overweight	$105
Jan-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$87
Dec-13-22	Resumed	BofA Securities	Neutral	$85
Dec-09-22	Downgrade	DZ Bank	Buy → Hold	$90
Oct-31-22	Upgrade	Barclays	Underweight → Equal Weight	$60 → $76
Oct-28-22	Upgrade	Truist	Hold → Buy	$76 → $91
Oct-28-22	Upgrade	Piper Sandler	Neutral → Overweight	$79 → $96
Oct-28-22	Reiterated	Wells Fargo	Equal Weight	$74 → $75
Oct-28-22	Reiterated	RBC Capital Mkts	Outperform	$79 → $82
Oct-28-22	Reiterated	JP Morgan	Overweight	$80 → $87
Oct-28-22	Reiterated	Jefferies	Buy	$78 → $86
Oct-28-22	Reiterated	Cowen	Outperform	$75 → $80

Show Previous Ratings

Today 08:30AM	Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis (Business Wire)
08:06AM	Flora Growth Corp. (NASDAQ:FLGC) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-16-24 02:27PM	Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch (InvestorPlace)
May-14-24 10:09AM	Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy (Business Wire)
08:45AM	Gilead Sciences: Native Health Navigator Program Connects Tribes to Cancer Care (ACCESSWIRE)
12:41PM	Loading…
May-13-24 12:41PM	One stock is dragging down the S&P 500's earnings growth (Yahoo Finance)
May-10-24 09:00AM	Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know (Zacks)
May-09-24 04:05PM	Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program (Business Wire)
04:05PM	Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program (Business Wire)
09:45AM	Gilead's FOCUS Program Helps Zero In on Early HIV Detection (ACCESSWIRE)
06:49AM	Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine (InvestorPlace)
01:07AM	Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight (GuruFocus.com)
May-07-24 09:45AM	Gilead Helps Put African Nation on Path To Eliminate Hepatitis C (ACCESSWIRE)
08:30AM	Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024 (Business Wire)
May-06-24 12:39PM	Bargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce Back (InvestorPlace)
07:38AM	Loading…
May-04-24 07:38AM	23 Most Profitable Stocks of the Last 12 Months (Insider Monkey)
May-03-24 08:11PM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
02:00PM	Forbes Has Listed Gilead as One of America's Best Employers for Diversity (ACCESSWIRE)
May-02-24 11:29AM	UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating (MT Newswires)
May-01-24 02:38PM	Shhh! 3 Secret Biotech Stocks Flying Below Wall Street's Radar (InvestorPlace)
10:53AM	Deutsche Bank Adjusts Price Target on Gilead Sciences to $73 From $75 (MT Newswires)
10:19AM	Maxim Adjusts Price Target on Gilead Sciences to $85 From $90 (MT Newswires)
08:25AM	Redburn Atlantic Adjusts Price Target on Gilead Sciences to $117 From $120 (MT Newswires)
Apr-30-24 04:05PM	Gilead Sciences to Present at Upcoming Investor Conferences (Business Wire)
12:01PM	Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-29-24 09:00AM	Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:18AM	Barclays Adjusts Price Target on Gilead Sciences to $76 From $80 (MT Newswires)
06:01AM	Gilead expands FDA label for Biktarvy with Phase I pregnant HIV patient data (Clinical Trials Arena)
Apr-28-24 05:50PM	American Politicians are Selling These 10 Stocks (Insider Monkey)
Apr-26-24 04:31PM	Analyst Report: Gilead Sciences, Inc. (Morningstar Research)
04:10PM	Loading…
04:10PM	Gilead Gives Up Big Gains As Covid Drug Drives Its Beat Again (Investor's Business Daily)
11:44AM	3 Dividend Stocks to Buy at a 52-Week Low in April (InvestorPlace)
10:45AM	TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90 (MT Newswires)
10:24AM	Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat (Zacks)
10:09AM	Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95 (MT Newswires)
10:08AM	RBC Capital Adjusts Gilead Sciences' Price Target to $74 From $76 (MT Newswires)
09:59AM	Morgan Stanley Adjusts Price Target on Gilead Sciences to $78 From $80 (MT Newswires)
09:14AM	Gilead Sciences Receives FDA Approval for Updated Label of Biktarvy (MT Newswires)
08:11AM	Q1 2024 Gilead Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
08:00AM	FDA Approves Biktarvy Label Update With Data for Pregnant Adults With HIV (Business Wire)
03:35AM	Gilead Sciences Inc (GILD) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ... (GuruFocus.com)
Apr-25-24 09:45PM	Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript (Motley Fool)
06:00PM	Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:49PM	Gilead Beats Earnings Expectations After Rocky Quarter (Barrons.com)
05:41PM	Gilead Sciences Inc (GILD) Q1 2024 Earnings: Misses Analyst EPS Estimates Amid Significant ... (GuruFocus.com)
05:15PM	Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:59PM	UPDATE 1-Gilead posts quarterly loss on acquisition charge, revenue rises 5% (Reuters)
04:50PM	Gilead Sciences Q1 Tops Estimates, Updates Outlook (MT Newswires)
04:40PM	Gilead Notches A Quarterly Beat On The Back Of Its Covid Drug, Again (Investor's Business Daily)
04:14PM	Gilead: Q1 Earnings Snapshot (Associated Press Finance)
04:11PM	Gilead posts quarterly loss on acquisition charge, revenue rises 5% (Reuters)
04:07PM	Will Gilead's Big Veklury Beat Offset A Cancer Drug Miss? (Investor's Business Daily)
04:02PM	Gilead posts quarterly loss, revenue rises 5% (Reuters)
04:02PM	Gilead Sciences Announces First Quarter 2024 Financial Results (Business Wire)
Apr-22-24 01:57PM	Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect? (Zacks)
09:16AM	Insights Into Gilead (GILD) Q1: Wall Street Projections for Key Metrics (Zacks)
Apr-19-24 05:50PM	Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know (Zacks)
Apr-18-24 06:33PM	US FDA mandates label updates on CAR-T cancer therapies (Reuters)
06:00PM	Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
01:45PM	Gilead Sciences Publishes 2023 ESG Impact Report (ACCESSWIRE)
10:01AM	Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-17-24 02:03AM	GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA (PR Newswire)
Apr-16-24 09:00AM	Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Apr-15-24 08:00AM	Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq? (Motley Fool)
01:06AM	GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA (PR Newswire)
12:22AM	GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG KONG (PR Newswire)
Apr-12-24 06:00PM	Gilead Sciences (GILD) Stock Moves -0.84%: What You Should Know (Zacks)
Apr-11-24 09:15AM	Biotech Innovations Paving the Way in Breast Cancer Fight (PR Newswire)
Apr-10-24 06:09PM	12 Best Depressed Stocks To Buy in 2024 (Insider Monkey)
Apr-09-24 06:15PM	Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider (Zacks)
02:40PM	3 Stocks at 52-Week Lows Poised for a Powerful Rebound (InvestorPlace)
07:37AM	11 Best Biotech ETFs To Buy (Insider Monkey)
Apr-08-24 04:05PM	Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024 (Business Wire)
Apr-06-24 06:49AM	3 No-Brainer Dividend Stocks to Buy in April (Motley Fool)
Apr-05-24 08:30AM	Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows (Motley Fool)
Apr-03-24 09:00AM	Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
Apr-02-24 06:00PM	Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know (Zacks)
09:15AM	Gilead Sciences Champions Equal Pay (ACCESSWIRE)
Mar-28-24 08:30AM	FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six (Business Wire)
07:00AM	Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program (GlobeNewswire)
06:45AM	Gilead bets on Xilio cancer drug as biotech restructures (BioPharma Dive)
06:45AM	7 Value Stocks to Buy at a 52-Week Low in March (InvestorPlace)
Mar-26-24 09:15AM	Winn Awards Help Physicians Solve Healthcare Disparities (ACCESSWIRE)
05:15AM	20 Biggest Health Care Companies in Australia, 2024 (Insider Monkey)
Mar-25-24 06:00PM	Gilead Sciences (GILD) Stock Moves -0.04%: What You Should Know (Zacks)
Mar-22-24 09:18AM	Gilead Sciences Announces Completion of Acquisition of CymaBay (Business Wire)
Mar-20-24 09:00AM	Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know (Zacks)
Mar-19-24 06:00PM	Gilead Sciences (GILD) Rises But Trails Market: What Investors Should Know (Zacks)
09:05AM	Gilead Helps Launch Türkiyes First HIV Testing Week (ACCESSWIRE)
Mar-18-24 07:29PM	Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant (Business Wire)
08:00AM	How To Trade Stocks: Do You Know The Seven Most Important Words On Wall Street? (Investor's Business Daily)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
08:15AM	2 Top Dividend Stocks to Buy Hand Over Fist (Motley Fool)
Mar-15-24 06:00AM	Gilead CAR-T cancer therapy capacity to quadruple by 2026 (Reuters)
Mar-14-24 09:38AM	12 Most Profitable Biotech Stocks To Invest In (Insider Monkey)
Mar-13-24 06:00PM	Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know (Zacks)
07:03AM	Gilead Sciences Inc's Dividend Analysis (GuruFocus.com)
Mar-12-24 08:45AM	Gilead Science Supports Increasing Diversity in Clinical Trials: 2024 Toward Health Equity Oncology Grant Supports 36 Global Organizations (ACCESSWIRE)
Mar-11-24 08:24AM	Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer (Business Wire)

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GILEAD SCIENCES, INC.	10% Owner	Apr 02 '24	Buy	0.76	485,250	368,790	7,345,473	Apr 03 06:50 PM
Parsey Merdad	Chief Medical Officer	Apr 01 '24	Sale	72.96	2,000	145,920	96,304	Apr 02 06:38 PM
Parsey Merdad	Chief Medical Officer	Feb 29 '24	Sale	72.74	8,230	598,624	92,706	Feb 29 06:35 PM
Parsey Merdad	Chief Medical Officer	Feb 28 '24	Sale	73.18	2,000	146,360	100,936	Feb 29 06:35 PM
GILEAD SCIENCES, INC.	10% Owner	Feb 12 '24	Buy	22.00	910,000	20,020,000	4,126,119	Feb 13 05:48 PM
GILEAD SCIENCES, INC.	10% Owner	Jan 29 '24	Buy	21.00	15,238,095	319,999,995	30,061,124	Jan 31 05:00 PM
Dickinson Andrew D	Chief Financial Officer	Jan 16 '24	Sale	85.78	5,000	428,900	101,534	Jan 17 06:01 PM
Mercier Johanna	Chief Commercial Officer	Jan 09 '24	Sale	85.23	8,242	702,466	82,729	Jan 10 03:58 PM
Dickinson Andrew D	Chief Financial Officer	Oct 17 '23	Sale	80.00	5,000	400,017	104,003	Oct 18 04:31 PM
Parsey Merdad	Chief Medical Officer	Sep 12 '23	Sale	76.99	1,501	115,562	70,130	Sep 13 06:50 PM
Dickinson Andrew D	Chief Financial Officer	Jul 20 '23	Sale	80.00	5,000	400,000	107,587	Jul 21 05:30 PM
GILEAD SCIENCES, INC.	10% Owner	Jun 28 '23	Buy	19.26	1,010,000	19,452,600	14,823,029	Jun 30 03:12 PM
GILEAD SCIENCES, INC.	10% Owner	Jun 27 '23	Buy	3.75	2,930,870	10,990,762	16,635,286	Jun 28 05:17 PM
Parsey Merdad	Chief Medical Officer	Jun 13 '23	Sale	76.90	1,485	114,197	29,402	Jun 14 05:48 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

DVA

DaVita Inc

GILD

Gilead Sciences, Inc.

Upgrade your FINVIZ experience